Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to -$22.4 million.

  • Relay Therapeutics' Net Cash Flow fell 22682.5% to -$22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 1400181.41%. This contributed to the annual value of -$20.0 million for FY2024, which is 15270.53% down from last year.
  • Relay Therapeutics' Net Cash Flow amounted to -$22.4 million in Q3 2025, which was down 22682.5% from $19.9 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Net Cash Flow ranged from a high of $246.9 million in Q3 2022 and a low of -$202.8 million during Q4 2022
  • Its 5-year average for Net Cash Flow is -$18.7 million, with a median of -$11.7 million in 2022.
  • Over the last 5 years, Relay Therapeutics' Net Cash Flow had its largest YoY gain of 88358.3% in 2022, and its largest YoY loss of 113123.03% in 2022.
  • Quarter analysis of 5 years shows Relay Therapeutics' Net Cash Flow stood at $51.6 million in 2021, then plummeted by 493.42% to -$202.8 million in 2022, then skyrocketed by 96.26% to -$7.6 million in 2023, then crashed by 269.73% to -$28.1 million in 2024, then grew by 20.28% to -$22.4 million in 2025.
  • Its Net Cash Flow stands at -$22.4 million for Q3 2025, versus $19.9 million for Q2 2025 and -$30.7 million for Q1 2025.